scholarly journals Association between diabetes status and subsequent onset of glaucoma in postmenopausal women

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Younhea Jung ◽  
Kyungdo Han ◽  
Kyoung Ohn ◽  
Da Ran Kim ◽  
Jung II Moon
Keyword(s):  
Postmenopausal Women ◽  
Screening Program ◽  
Diabetes Group ◽  
Onset Diabetes ◽  
Hazard Ratios ◽  
Diabetes Status ◽  
Increased Risk ◽  
Subgroup Analyses ◽  
Health Screening Program ◽  
New Onset

AbstractThe purpose of this study was to analyze the risk of glaucoma based on diabetes status using a large nationwide longitudinal cohort of postmenopausal women. This study included 1,372,240 postmenopausal women aged ≥ 40 years who underwent National Health Screening Program in 2009. Subjects were classified into the following 5 categories based on diabetes status: no diabetes, impaired fasting glucose (IFG), new onset diabetes, diabetes treated with oral hypoglycemic medication, and diabetes treated with insulin. Subjects were followed from 2005 through 2018, and hazard ratios of glaucoma onset were calculated for each group. Subgroup analyses of subjects stratified by age, smoking, drinking, hypertension, and dyslipidemia were performed. During the follow up period, 42,058 subjects developed glaucoma. The adjusted hazard ratio was 1.061 (95% CI, 1.036–1.086) in the IFG group, 1.151 (95% CI, 1.086–1.220) in the new onset diabetes group, 1.449 (95% CI, 1.406–1.493) in the diabetes treated with oral hypoglycemic medication group, and 1.884(95% CI, 1.777–1.999) in the diabetes treated with insulin group compared to the no diabetes group. The results were consistent in subgroup analyses after stratifying by age, lifestyle factors (smoking and drinking), and comorbidities (hypertension and dyslipidemia). Diabetes status is associated with increased risk of glaucoma development in postmenopausal women.

scholarly journals Changes in Metabolic Syndrome Status and Breast Cancer Risk: A Nationwide Cohort Study

Cancers ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 1177
Author(s):  
In Young Choi ◽  
Sohyun Chun ◽  
Dong Wook Shin ◽  
Kyungdo Han ◽  
Keun Hye Jeon ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metabolic Syndrome ◽  
Proportional Hazards ◽  
Screening Program ◽  
Cox Proportional Hazards ◽  
Cox Proportional Hazards Models ◽  
Hazard Ratios ◽  
Increased Risk ◽  
Health Screening Program ◽  
Design And Methods

Objective: To our knowledge, no studies have yet looked at how the risk of developing breast cancer (BC) varies with changes in metabolic syndrome (MetS) status. This study aimed to investigate the association between changes in MetS and subsequent BC occurrence. Research Design and Methods: We enrolled 930,055 postmenopausal women aged 40–74 years who participated in a biennial National Health Screening Program in 2009–2010 and 2011–2012. Participants were categorized into four groups according to change in MetS status during the two-year interval screening: sustained non-MetS, transition to MetS, transition to non-MetS, and sustained MetS. We calculated multivariable-adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for BC incidence using the Cox proportional hazards models. Results: At baseline, MetS was associated with a significantly increased risk of BC (aHR 1.11, 95% CI 1.06–1.17) and so were all of its components. The risk of BC increased as the number of the components increased (aHR 1.46, 95% CI 1.26–1.61 for women with all five components). Compared to the sustained non-MetS group, the aHR (95% CI) for BC was 1.11 (1.04–1.19) in the transition to MetS group, 1.05 (0.96–1.14) in the transition to non-MetS group, and 1.18 (1.12–1.25) in the sustained MetS group. Conclusions: Significantly increased BC risk was observed in the sustained MetS and transition to MetS groups. These findings are clinically meaningful in that efforts to recover from MetS may lead to reduced risk of BC.

scholarly journals A Neutral Risk on the Development of New-Onset Diabetes Mellitus (NODM) in Taiwanese Patients with Dyslipidaemia Treated with Fibrates

2012 ◽  
Vol 2012 ◽  
pp. 1-5 ◽  
Author(s):  
Chien-Ying Lee ◽  
Kuang-Hua Huang ◽  
Chun-Che Lin ◽  
Tung-Han Tsai ◽  
Hung-Che Shih
Keyword(s):  
Diabetes Mellitus ◽  
Health Insurance ◽  
Research Database ◽  
Onset Diabetes ◽  
Hazard Ratios ◽  
Increased Risk ◽  
The Relationship ◽  
Insurance Database ◽  
New Onset Diabetes Mellitus ◽  
New Onset

There are no data on the incidence of new-onset diabetes mellitus (NODM ) in nondiabetic dyslipidaemia patients treated with fibrates. The aim of our study was to clarify these issues, to investigate the relationship between NODM and fibrate and whether the fibrates lead to increased risk for developing NODM. A retrospective cohort study was conducted by analyzing the Longitudinal Health Insurance Database (LHID 2005) of the National Health Insurance Research Database (NHIRD) from 2005 to 2010 to investigate all fibrate prescriptions for patients with dyslipidaemia. We estimated the hazard ratios (HRs) of NODM associated with fibrate use. We identified 145 NODM patients among 3,815 dyslipidaemic patients in the database for the study period. The risk estimates for NODM for users of fenofibrate (HR 1.30; 95% CI 0.82, 2.05) and gemfibrozil (HR 0.771; 95% CI 0.49, 1.22) were not associated with an increased risk of developing NODM (P>0.05). Our results revealed that patients with dyslipidaemia who took fenofibrate and gemfibrozil had a neutral risk of NODM. The reasons may be associated with the fibrates have the properties that activate PPARαand in some cases also activated PPARγ, leading to showing a neutral risk of NODM.

Abstract 658: New Onset Diabetes Does Not Pose Additional Risk - Analysis Of 15,111 Treated Hypertensive Patients With 40 Year Follow-up.

Hypertension ◽  
2014 ◽  
Vol 64 (suppl_1) ◽  
Author(s):  
Stefanie Lip
Keyword(s):  
Alkaline Phosphatase ◽  
Hospital Admissions ◽  
Cox Proportional Hazards ◽  
Outcome Analysis ◽  
Gamma Glutamyl Transpeptidase ◽  
Hypertensive Patients ◽  
Onset Diabetes ◽  
Diabetes Status ◽  
New Onset

Objective: It is unclear whether new onset diabetes (NOD) is a separate entity associated with excess risk in hypertensive patients. Methods: We studied 15111 hypertensive patients with up to 40 year follow-up at the Glasgow BP Clinic database. Diabetes status was defined based on hospital admissions for any diabetes related diagnosis or prescription of anti-diabetic drugs or diabetes monitoring materials. The date at first hospital encounter either for prescription or admission was considered as the onset of diabetes. NOD was classified into early and late (diagnosis <10yrs or >10years from first clinic visit). Cause-specific outcome analysis was performed using multivariate-adjusted Cox proportional hazards (Cox-PH) models. In order to address any potential competing risk introduced due to the long follow-up period, an additional composite end point of all-cause mortality+NOD was analysed. Results: There were 2521(17%) patients with DM, of whom 2061(14%) had NOD. The incidence rate of NOD was 9.2 per 1000 person-years. Prevalence of early NOD was 898 (6%) and late NOD 1163 (8%). The total time at risk was 239,952 person-years with a median survival time of 28.04 years (IQR: 16.24-39.95). There were 5225 deaths (52% from cardiovascular causes) during the follow-up period. Independent predictors of new-onset diabetes in order of decreasing significance were baseline glucose, BMI, age, alanine transaminase, alkaline phosphatase, gamma glutamyl transpeptidase and bilirubin. Of these age, glucose, BMI and alkaline phosphatase remained top predictors for the composite outcome of NOD+all-cause death. The mortality risk was the highest in those with prevalent DM (HR=1.5[95%CI=1.2;1.9]) and lowest in those with late NOD (0.79[0.68;0.92]). Early NOD and non-diabetic subjects had similar risks. Conclusions: Indices of liver function tests predict the risk of NOD and mortality in addition to BMI and baseline glucose. The risk posed by NOD is related to duration of diabetes primarily indicating the importance of efforts to delay onset of NOD.

scholarly journals Serum alkaline phosphatase levels and the risk of new-onset diabetes in hypertensive adults

2020 ◽  
Vol 19 (1) ◽  
Author(s):  
Yuanyuan Zhang ◽  
Chun Zhou ◽  
Jianping Li ◽  
Yan Zhang ◽  
Di Xie ◽  
...  
Keyword(s):  
Alkaline Phosphatase ◽  
Fasting Glucose ◽  
Serum Alkaline Phosphatase ◽  
Positive Association ◽  
Trial Registration ◽  
Clinical Trial Registration ◽  
Onset Diabetes ◽  
Increased Risk ◽  
New Onset

Abstract Background The association between alkaline phosphatase (ALP) and incident diabetes remains uncertain. Our study aimed to investigate the prospective relation of serum ALP with the risk of new-onset diabetes, and explore possible effect modifiers, in hypertensive adults. Methods A total 14,393 hypertensive patients with available ALP measurements and without diabetes and liver disease at baseline were included from the China Stroke Primary Prevention Trial (CSPPT). The primary outcome was new-onset diabetes, defined as physician-diagnosed diabetes or use of glucose-lowering drugs during follow-up, or fasting glucose ≥ 7.0 mmol/L at the exit visit. The secondary study outcome was new-onset impaired fasting glucose (IFG), defined as FG < 6.1 mmol/L at baseline and ≥ 6.1 but < 7.0 mmol/L at the exit visit. Results Over a median of 4.5 years follow-up, 1549 (10.8%) participants developed diabetes. Overall, there was a positive relation of serum ALP and the risk of new-onset diabetes (per SD increment, adjusted OR, 1.07; 95% CI: 1.01, 1.14) and new-onset IFG (per SD increment, adjusted OR, 1.07; 95% CI: 1.02, 1.14). Moreover, a stronger positive association between baseline ALP (per SD increment) with new-onset diabetes was found in participants with total homocysteine (tHcy) < 10 μmol/L (adjusted OR, 1.24; 95% CI: 1.10, 1.40 vs. ≥ 10 μmol/L: adjusted OR, 1.03; 95% CI: 0.96, 1.10; P-interaction = 0.007) or FG ≥ 5.9 mmol/L (adjusted OR, 1.16; 95% CI: 1.07, 1.27 vs. < 5.9 mmol/L: adjusted OR, 1.00; 95% CI: 0.93, 1.08; P-interaction = 0.009) Conclusions In this non-diabetic, hypertensive population, higher serum ALP was significantly associated with the increased risk of new-onset diabetes, especially in those with lower tHcy or higher FG levels. Clinical Trial Registration-URL Trial registration: NCT00794885 (clinicaltrials.gov). Retrospectively registered November 20, 2008.

scholarly journals High Serum PCSK9 Is Associated With Increased Risk of New-Onset Diabetes After Transplantation in Renal Transplant Recipients

Diabetes Care ◽  
2017 ◽  
Vol 40 (7) ◽  
pp. 894-901 ◽  
Author(s):  
Michele F. Eisenga ◽  
Dorien M. Zelle ◽  
John H. Sloan ◽  
Carlo A.J.M. Gaillard ◽  
Stephan J.L. Bakker ◽  
...  
Keyword(s):  
Renal Transplant ◽  
High Serum ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Onset Diabetes ◽  
Increased Risk ◽  
New Onset

scholarly journals Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes: A nationwide cohort study

Hepatology ◽  
2014 ◽  
Vol 60 (3) ◽  
pp. 807-814 ◽  
Author(s):  
Yi-Wen Huang ◽  
Sien-Sing Yang ◽  
Szu-Chieh Fu ◽  
Ting-Chuan Wang ◽  
Cheng-Kai Hsu ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Cohort Study ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Onset Diabetes ◽  
Increased Risk ◽  
Chronic Hepatitis C Patients ◽  
New Onset

scholarly journals Subjective motoric complaints and new onset slow gait

2020 ◽  
Author(s):  
Joe Verghese ◽  
Emmeline Ayers
Keyword(s):  
Primary Outcome ◽  
Walking Speed ◽  
Risk Assessments ◽  
Recall Bias ◽  
Normal Range ◽  
Hazard Ratios ◽  
Increased Risk ◽  
Age And Sex ◽  
New Onset

Abstract Background While reports of mobility problems are common with aging, their relationship to new onset of slow gait is unknown. Our objective was to examine the validity of subjective motoric complaints for predicting the incidence of slow gait. Methods Ambulatory community-residing participants (mean age 76.6, 55% women) with gait speeds in the normal range enrolled in an aging cohort. Five subjective motoric complaints were assessed. Incident slow gait (walking speed 1 standard deviation below age and sex means) was the primary outcome. Results Of the 548 participants at baseline, 90 had prevalent slow gait and 253 participants (73.7%) reported one or more subjective motoric complaints. Subjective motoric complaints were more common in women than men (1.78 vs. 1.23). Over a median follow-up of 3.34 years, 68 participants developed new onset slow gait. All five questions predicted incident slow gait (adjusted hazard ratios varying from 2.26 to 4.44). More subjective motoric complaints were associated with increased risk of developing incident slow gait (hazard ratio per complaint 1.81). Predictive validity of subjective motoric complaints for incident slow gait was unchanged when using alternate outcome definitions, accounting for diagnostic misclassification, recall bias or adjusting for multiple confounders. Conclusions Subjective motoric complaints are a harbinger of mobility disability, and can help improve clinical risk assessments and identify high risk individuals for interventions to prevent onset of slow gait.

scholarly journals Hypertension, Diabetes and the Risk of Cardiac and Cerebrovascular Events: a prospective cohort study

2020 ◽  
Author(s):  
Yao Li ◽  
Junjuan Li ◽  
Jianli Wang ◽  
Maoxiang Zhao ◽  
Chi Wang ◽  
...  
Keyword(s):  
Cox Regression ◽  
Incidence Density ◽  
Cerebrovascular Events ◽  
Diabetes Status ◽  
Increased Risk ◽  
Two Factors ◽  
Baseline Information ◽  
Cerebral Ischemic ◽  
New Onset

Abstract Background Hypertension and diabetes are both risk factors of cardiac and cerebrovascular events (CCVEs), but the combination of those two factors had not been certified the relationships relevant to CCVEs. The objective of this study is to determine the relationships of hypertension, diabetes and CCVEs.Methods 78380 participants from Kailuan cohort had been analyzed. Baseline information was collected in the health exam and all the participants were regularly followed-up for every two years during 8.96 ± 0.75 years. Participants were divided into six groups according to their hypertension and diabetes status (normal, baseline or follow-up). The incidence of new-onset cerebral ischemic stroke (CI), stroke and CCVEs were respectively calculated. Multiple Cox Regression and Cum Hazard were performed to analyze the hazard ratio for risk of new-onset CI, stroke and CCVEs in each group adjusting for traditional cardiovascular risk markers.Results In total, 78380 participants (including 61950 men) with a mean age of 56.74 at baseline were enrolled in this study. During about 9 years of follow-up, 3734 CCVEs, 2972 stroke and 2340 CI occurred among all the patients, with the incidence density (Per 1,000 years) of 5.29, 4.07 and 3.32. In patients with baseline hypertension and diabetes, hazard ratios (HRs) and 95% confidence intervals (95%CIs) of new-onset CI (HR = 2.45, 95%CI: 1.93, 3.11), stroke (HR = 2.39, 95%CI: 1.92, 2.98) and CCVEs (HR = 2.08, 95% CI: 1.72, 2.52)were higher than the other groups (P < 0.001). Patients with baseline hypertension or diabetes and follow-up diabetes or hypertension had higher risk of CI, stroke and CCVEs than those who with baseline disease only.Conclusion Hypertension and diabetes alone, especially the combination of these two diseases at baseline and during follow up, contributed significantly to increased risk of new-onset CI, stroke and CCVEs during the 9 years follow up in this cohort.

Sign in / Sign up

Export Citation Format

Share Document